Conceptus wins against Hologic in patent dispute; Journal publishes data on InfraReDx's LipiScan;

> A jury has awarded Conceptus $18.8 million in damages in a patent suit against Hologic ($HOLX). The suit centered around the Adiana permanent contraceptive system, which Conceptus alleged infringed upon a patent covering its Essure product. Hologic release | Report

> InfraReDx has announced that new data for its LipiScan coronary imaging system was published in the journal Circulation: Cardiovascular Interventions. Near-infrared spectroscopy (NIRS) with the LipiScan system detected lipid core plaques (LCP), which are linked to an increased risk of heart attack during or after percutaneous coronary intervention. LipiScan is the first and only FDA-cleared system to provide interventional cardiologists with a Chemogram--a two-dimensional map of LCP--within the imaged vessel using NIRS. InfraReDx release

> Wright Medical Group ($WMGI) has selected Julie Tracy as senior VP and chief communications officer, effective immediately. Wright Medical release

> Boston Scientific ($BSX) has completed enrollment in a study to evaluate its WallFlex Biliary RX fully covered stent for the treatment of benign bile duct strictures. Boston Scientific release

> SABIRMEDICAL has tapped Dr. Wolfgang Reim as chairman of the board of directors. The company, which is based in the Bioincubator PCB-Santander in the Barcelona Science Park, specializes in developing minimally invasive technology for patient diagnosis and monitoring. SABIRMEDICAL release

> Durham, NC-based Chesson Labs has raised $1.45 million in a second round of financing targeting $2 million. The current round of financing started in 2009 after FDA clearance for its liquid bandage product. News

And Finally... A medical device that looks like a baby harp seal. The Los Angeles Times looks at whether people would want to hang out with such a device and ponders whether it's a good idea. Piece

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.